Article Versions Notes

Kim J-M, Noh J, Park J-W, Chung H, Kim K-A, Park SB, Lee J-S, Park J-Y. Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran. Pharmaceutics. 2022; 14(2):257. https://doi.org/10.3390/pharmaceutics14020257

Kim, Jong-Min, Jihyeon Noh, Jin-Woo Park, Hyewon Chung, Kyoung-Ah Kim, Seung Bin Park, Jun-Seok Lee, and Ji-Young Park. 2022. "Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran" Pharmaceutics 14, no. 2: 257. https://doi.org/10.3390/pharmaceutics14020257

Kim, J.-M., Noh, J., Park, J.-W., Chung, H., Kim, K.-A., Park, S. B., Lee, J.-S., & Park, J.-Y. (2022). Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran. Pharmaceutics, 14(2), 257. https://doi.org/10.3390/pharmaceutics14020257